System approach to modeling metabolite formation from parent drug: A working example with methotrexate

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 8, 2002, Pages 481-486

  Dedik L ^a,b   Ďurišová, Mária ^a,b  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Metabolite formation; Methotrexate; Model; Parent metabolite system

Indexed keywords

7 HYDROXYMETHOTREXATE; DRUG METABOLITE; METHOTREXATE;

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; METHODOLOGY; PSORIASIS; STATISTICAL MODEL;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DATABASES, FACTUAL; FOLIC ACID ANTAGONISTS; HUMANS; INTERNET; LINEAR MODELS; METHOTREXATE; MODELS, BIOLOGICAL; PSORIASIS; SOFTWARE; TIME FACTORS;

EID: 0036813989     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2002.24.8.705067     Document Type: Article

References (27)

1. Bellissant, E., Chau, N.P., Thuillez, C., Giudicelli, J.F. Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers. Arch Mal Coeur Vaiss 1990, 83: 1285-9.
2. Christensen, B., Nielsen, J. Metabolic network analysis. A powerful tool in metabolic engineering. Adv Biochem Eng Biotechnol 2000, 66: 209-31.
3. Lindsey, J.K., Wang, J., Jones, B., Byrom, W.D., Hind, I.D. Simultaneous modelling of flosequinan and its metabolite. Eur J Clin Pharmacol 2000, 55: 827-36.
4. Sun, L., Lau, C.E. Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. Drug Metab Dispos 2001, 29: 1183-9.
5. Evans, N.D., Godfrey, K.R., Chapman, M.J., Chappell, M.J., Aarons, L., Duffull, SB. An identifiability analysis of a parent-metabolite pharmacokinetic model for invabradine. J Pharmacokin Pharmacodyn 2001, 28: 93-105.
6. Dedík, L., Durišová, M. CXT - A programme for analysis of linear dynamic systems in the frequency domain. Int J Bio-Med Comput 1995, 39: 231-41.
7. Dedík, L., Durišová, M. CXT-MAIN: A software package for determination of the analytical form of the pharmacokinetic system weighting function. Comput Methods Programs Biomed 1996, 51: 183-92.
8. Dedík, L., Durišová, M. System Approach in Technical, Environmental and Biomedical Studies. Publishing House of Slovak University of Technology: Bratislava 1999.
9. Durišová, M., Dedík, L. Comparative study of human pentacaine pharmacokinetics in time and frequency domain. Methods Find Exp Clin Pharmacol 1994, 16: 219-32.
10. Dedík. L., Durišová, M. Frequency response method in pharmacokinetics. J Pharmacokin Biopharm 1994, 22: 293-307.
11. Durišová, M., Dedík, L., Balan, M. Building a structured model of a complex pharmacokinetic system with time delays. Bull Math Biol 1995, 57: 787-808.
12. Durišová, M., Dedík, L. Modeling in frequency domain used for assessment of in vivo dissolution profile. Pharm Res 1997, 14: 860-4.
13. Durišová, M., Dedík, L., Bátorová, A., Sakalová, A., Hedera, J. Pharmacokinetics of Factor VIII in hemophilia A patients assessed by frequency response method. Methods Find Exp Clin Pharmacol 1998, 20: 217-26.
14. Dedík, L., Durišová, M., Srikusalanukul, W., McCulagh, P. Model of lymphocyte migration in merino ewes under physiological conditions. Physiol Res 1999, 48: 525-8.
15. Dedík, L., Durišová, M. Modeling drug absorption from entericcoated granules. Methods Find Exp Clin Pharmacol 2001, 23: 213-7.
16. Dedík, L., Durišová, M. System-approach methods for modeling and testing similarity of in vitro dissolutions of drug dosage formulations. Comput Methods Programs Biomed 2002, 69: 49-55.
17. Chládek, J., Martínková, J., Šimková, M., Vaniecková, J., Koudelková, V., Noiecková, M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998, 53: 437-44.
18. Matzo, A., Monti, N.C., Vuksic, D. Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials. Eur J Clin Pharmacol 1999, 55: 627-31.
19. Karol, M.D., Goodrich. S. Metabolite formation pharmacokinetics: Rate and extent of metabolite formation determined by deconvolution. Pharm Res 1998, 5: 347-51.
20. Singh, M.G. Systems and Control Encyclopedia, Theory, Technology and Application. Pergamon Press: Oxford 1987.
21. Schoukens, J., Pintelon. R. Identification of Linear Systems. A Practical Guide for Accurate Modelling. Pergamon Press: Oxford 1991.
22. Canal, P., Gay, C., Dezeuze, A. et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996, 14: 2688-95.
23. Levy, E.C. Complex curve fitting. IRE Trans Automat Contr 1959, AC-4: 37-43.
24. Akaike, H. Information theory and an extension of the maximum likelihood principle. In: Second International Symposium on Inference Theory. Petrov, B.N., Csaki, F. (Eds). Akademiai Kiado: Budapest 1973, 267-81.
25. Segre, G. The sojourn time and its prospective use in pharmacology. J Pharmacokin Biopharm 1988, 16: 657-66.
26. Heaviside, O. On operators in mathematical physics. Proc R Soc London 1897, Ser A 54: 105-43.
27. Weiss, M. Analysis of metabolite formation pharmacokinetics after intravenous and oral administration of the parent drug using inverse Laplace transformation. Drug Metab Dispos 1998, 26: 562-5.